Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Enterprise Value (2020 - 2025)

Historic Enterprise Value for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to -$91.6 million.

  • Xeris Biopharma Holdings' Enterprise Value fell 3198.18% to -$91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.6 million, marking a year-over-year decrease of 3198.18%. This contributed to the annual value of -$71.6 million for FY2024, which is 114.56% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Enterprise Value of -$91.6 million as of Q3 2025, which was down 3198.18% from -$59.3 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Enterprise Value peaked at -$58.4 million during Q1 2025, and registered a low of -$132.1 million during Q1 2022.
  • In the last 5 years, Xeris Biopharma Holdings' Enterprise Value had a median value of -$87.4 million in 2024 and averaged -$87.3 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 14542.84% in 2021, then surged by 4059.74% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Enterprise Value (Quarter) stood at -$102.4 million in 2021, then fell by 19.07% to -$122.0 million in 2022, then skyrocketed by 40.6% to -$72.5 million in 2023, then grew by 1.15% to -$71.6 million in 2024, then fell by 27.89% to -$91.6 million in 2025.
  • Its last three reported values are -$91.6 million in Q3 2025, -$59.3 million for Q2 2025, and -$58.4 million during Q1 2025.